Pharmacological characterization of designer cathinones in vitro

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 458-470

  Simmler, L D ^a   Buser, T A ^a   Donzelli, M ^a   Schramm, Y ^a   Dieu, L H ^a   Huwyler, J ^a   Chaboz, S ^b   Hoener, M C ^b   Liechti, Matthias E ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

amphetamine; cathinone; designer drug; dopamine; legal high; monoamine transporter; noradrenaline; serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE DERIVATIVE; BUTYLONE; CATHINONE; COCAINE; DESIGNER DRUG; DOPAMINE 1 RECEPTOR; ETHYLONE; FLEPHEDRONE; METHYLONE; MONOAMINE OXIDASE INHIBITOR; NAPHYRONE; NORADRENALIN UPTAKE INHIBITOR; PYROVALERONE; SEROTONIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER;

ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABUSE; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; MONOAMINE RELEASE; NEUROTRANSMISSION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

AMPHETAMINES; BLOOD-BRAIN BARRIER; CELL LINE; DESIGNER DRUGS; DOPAMINE; HEK293 CELLS; HUMANS; NOREPINEPHRINE; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; SEROTONIN; STREET DRUGS;

EID: 84871531590     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02145.x     Document Type: Article

References (60)

1. Aarde SA, Wright MJ, Buczynski MW, Angrish D, Parsons LH, Houseknecht KL, et al,. (2011). Behavioral and termoregulatory effects of novel cathinone derivative drugs 4-MMC and MDPV. Neuropsychopharmacology 36: S441.
2. Acquas E, Pisanu A, Spiga S, Plumitallo A, Zernig G, Di Chiara G, (2007). Differential effects of intravenous R,S-(+/-)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its S(+)- and R(-)-enantiomers on dopamine transmission and extracellular signal regulated kinase phosphorylation (pERK) in the rat nucleus accumbens shell and core. J Neurochem 102: 121-132.
3. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB, (2011). In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther 337: 218-225.
5. Baumann MH, Ayestas MA, Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al,. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37: 1192-1203.
6. Brunt TM, Poortman A, Niesink RJ, van den Brink W, (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25: 1543-1547.
7. Carhart-Harris RL, King LA, Nutt DJ, (2011). A web-based survey on mephedrone. Drug Alcohol Depend 118: 19-22.
8. Cecchelli R, Dehouck B, Descamps L, Fenart L, Buee-Scherrer VV, Duhem C, et al,. (1999). In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 36: 165-178.
9. Coppola M, Mondola R, (2012). 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208: 12-15.
10. Cozzi NV, Foley KF, (2003). Methcathinone is a substrate for the serotonin uptake transporter. Pharmacol Toxicol 93: 219-225.
11. Cozzi NV, Sievert MK, Shulgin AT, Jacob P, 3rd, Ruoho AE, (1999). Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381: 63-69.
12. Dal Cason TA, Young R, Glennon RA, (1997). Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol Biochem Behav 58: 1109-1116.
13. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krahenbuhl S, Liechti ME, (2011). Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol (Phila) 49: 691-693.
14. Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, et al,. (2011). Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31: 16928-16940.
15. Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, et al,. (1999). Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 382: 45-49.
16. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ, (2011). Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther 338: 280-289.
17. Ghose AK, Viswanadhan VN, Wendoloski JJ, (1998). Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragment methods: an analysis of ALogP and CLogP methods. J Phys Chem A 102: 3762-3772.
18. Glennon RA, Yousif M, Naiman N, Kalix P, (1987). Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 26: 547-551.
19. Gosnell BA, Yracheta JM, Bell SM, Lane KE, (1996). Intravenous self-administration of cathinone by rats. Behav Pharmacol 7: 526-531.
20. 2 receptor agonists. Eur J Pharmacol 264: 325-330.
21. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al,. (2011). 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
22. Huang PK, Aarde SM, Angrish D, Houseknecht KL, Dickerson TJ, Taffe MA, (2012). Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 126: 168-175.
23. 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340: 286-294.
24. Hysek CM, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, et al,. (2012b). Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166: 2277-2288.
25. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al,. (2012c). Duloxetine inhibits effects of MDMA ('ecstasy') in vitro and in humans in a randomized placebo-controlled laboratory study. Plos ONE 7: e36476.
26. Johanson CE, Schuster CR, (1981). A comparison of the behavioral effects of l- and dl-cathinone and d-amphetamine. J Pharmacol Exp Ther 219: 355-362.
27. Kalix P, (1990). Pharmacological properties of the stimulant khat. Pharmacol Ther 48: 397-416.
28. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al,. (2011). Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
29. Kelly JP, (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 3: 439-453.
30. Liechti ME, Baumann C, Gamma A, Vollenweider FX, (2000a). Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
31. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-404.
32. Liechti ME, Gamma A, Vollenweider FX, (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161-168.
33. Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al,. (2008). Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324: 948-956.
34. Lopez-Arnau R, Martinez-Clemente J, Pubill D, Escubedo E, Camarasa J, (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167: 407-420.
35. Lyon RA, Glennon RA, Titeler M, (1986). 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 88: 525-526.
36. Martin WR, Sloan JW, Sapira JD, Jasinski DR, (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
37. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J, (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231-236.
38. Meltzer PC, Butler D, Deschamps JR, Madras BK, (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49: 1420-1432.
39. Montgomery T, Buon C, Eibauer S, Guiry PJ, Keenan AK, McBean GJ, (2007). Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines. Br J Pharmacol 152: 1121-1130.
40. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS, (2012). Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409-422.
41. Nagai F, Nonaka R, Satoh Hisashi Kamimura K, (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132-137.
42. 1 receptor antagonist treatment attenuates positive subjective effects of cocaine in humans: a randomized trial. Plos ONE 7: e30854.
43. Nichols DE, (2004). Hallucinogens. Pharmacol Ther 101: 131-181.
44. Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al,. (2011). TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A 108: 8485-8490.
45. Rothman RB, Baumann MH, (2006). Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Ann N Y Acad Sci 1074: 245-260.
46. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al,. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
47. Sano Y, Shimizu F, Abe M, Maeda T, Kashiwamura Y, Ohtsuki S, et al,. (2010). Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 225: 519-528.
48. Sano Y, Kashiwamura Y, Abe M, Dieu L, Huwyler J, Shimizu F, et al,. (2012). A stable human brain microvascular endothelial cell line retaining its barrier-specific nature, independent of the passage number. Clin Exp Neuroimmunol (in press).
49. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH, (2000). Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther 293: 870-878.
50. Spiller HA, Ryan ML, Weston RG, Jansen J, (2011). Clinical experience with and analytical confirmation of 'bath salts' and 'legal highs' (synthetic cathinones) in the United States. Clin Toxicol (Phila) 49: 499-505.
51. Steele TD, Nichols DE, Yim GK, (1987). Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36: 2297-2303.
52. Tatsumi M, Groshan K, Blakely RD, Richelson E, (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258.
53. Thornton SL, Gerona RR, Tomaszewski CA, (2012). Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol 8: 310-313.
54. Verrico CD, Miller GM, Madras BK, (2007). MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189: 489-503.
55. Watteron LR, Kufahl PR, Nemirovsky NE, Sewalia K, Olive MF, (2011). Potent reinforcing effects of the synthetic cathinone methylenedioxypyrovalerone (MDPV) in rats. Neuropsychopharmacology 36: S440.
56. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL, (2005). Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313: 848-854.
57. Widler P, Mathys K, Brenneisen R, Kalix P, Fisch HU, (1994). Pharmacodynamics and pharmacokinetics of khat: a controlled study. Clin Pharmacol Ther 55: 556-562.
58. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F, (2011). Mephedrone, new kid for the chop? Addiction 106: 154-161.
59. Woolverton WL, Johanson CE, (1984). Preference in rhesus monkeys given a choice between cocaine and d,l-cathinone. J Exp Anal Behav 41: 35-43.
60. Xie Z, Miller GM, (2009). A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther 330: 316-325.